TLDR Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
A 12-month study with 254 adults with severe alopecia areata found that baricitinib, a JAK inhibitor, led to significant hair regrowth in nasal (52%), genital (44%), and beard areas (53%). Participants also reported reduced bothersomeness of hair loss, initially rated high. These results suggest baricitinib's potential for treating hair loss beyond the scalp, offering a holistic approach for severe AA.
January 2024 in “International Journal of Molecular Sciences” Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.
March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
September 2025 in “International Journal of Molecular Sciences” International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.